Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuki Fukami

Showing results (141-150 of 177) with videos related to

Pageof 18
Sort By:
Toxicology Letters|November 5, 2013
Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injuryKentaro Matsuo, Eita Sasaki, Satonori Higuchi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 13, 2017
Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibodyShingo Oda, Yukiko Kato, Masahiko Hatakeyama, et al.
Clinical Pharmacology and Therapeutics|December 14, 2004
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivoTatsuki Fukami, Miki Nakajima, Ryoko Yoshida, et al.
Pharmacogenetics and Genomics|September 17, 2008
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genesTatsuki Fukami, Miki Nakajima, Taiga Maruichi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 25, 2015
CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126Masataka Nakano, Yasunari Fukushima, Shin-ichi Yokota, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 2, 2005
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributionsHiroyuki Yamanaka, Miki Nakajima, Tatsuki Fukami, et al.
Journal of Lipid Research|August 8, 2025
Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolismItsuki Yokoseki, Masataka Nakano, Kiamu Kurosawa, et al.
Clinical Biochemistry|August 22, 2017
Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injuryYu Yamaura, Naoyuki Tatsumi, Shingo Takagi, et al.
Life Sciences|August 27, 2021
Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humansYoshiyuki Sakai, Tatsuki Fukami, Mai Nagaoka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2023
Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human IntestineKeiya Hirosawa, Hijiri Fujioka, Gaku Morinaga, et al.
Pageof 18

Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
Toxicology Letters|November 5, 2013
Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injuryKentaro Matsuo, Eita Sasaki, Satonori Higuchi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 13, 2017
Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibodyShingo Oda, Yukiko Kato, Masahiko Hatakeyama, et al.
Clinical Pharmacology and Therapeutics|December 14, 2004
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivoTatsuki Fukami, Miki Nakajima, Ryoko Yoshida, et al.
Pharmacogenetics and Genomics|September 17, 2008
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genesTatsuki Fukami, Miki Nakajima, Taiga Maruichi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 25, 2015
CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126Masataka Nakano, Yasunari Fukushima, Shin-ichi Yokota, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 2, 2005
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributionsHiroyuki Yamanaka, Miki Nakajima, Tatsuki Fukami, et al.
Journal of Lipid Research|August 8, 2025
Chromatin remodeler BRD9 represses transcription of PPARα target genes, including CPT1A to suppress lipid metabolismItsuki Yokoseki, Masataka Nakano, Kiamu Kurosawa, et al.
Clinical Biochemistry|August 22, 2017
Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injuryYu Yamaura, Naoyuki Tatsumi, Shingo Takagi, et al.
Life Sciences|August 27, 2021
Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humansYoshiyuki Sakai, Tatsuki Fukami, Mai Nagaoka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2023
Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human IntestineKeiya Hirosawa, Hijiri Fujioka, Gaku Morinaga, et al.
Pageof 18